Scinai Immunotherapeutics Ltd.
- Marktkapitalisierung
- $1.05M
- Volumen
- 2.73M
- Nächster Ergebnistermin
- Nov 9, 2015
Scinai Immunotherapeutics Ltd. (SCNI) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $460.0K | n/a | +123.30% |
| EPS | -$240,00 | -$178,00 | -8375.86% |
Kennzahlen
- Geld
- 1.41
- Marktkapitalisierung
- 1.05M
- Umsatz (TTM)
- 1.49M
- Nettogewinn (TTM)
- -2.6M
- 2.08
- 28.07
- 0.06
- n/a
- KBV (TTM)
- 0.14
- KUV (TTM)
- 0.71
- Termin Quartalszahlen
- Nov 9, 2015
- Brief
- 1.98
- Volumen
- 2,730,471
- Ø Vol. (20D)
- 148,227
- Eröffnung
- 1.68
- Vortagesschluss
- 1.67
- Tagesspanne
- 1.65 - 1.78
- 52-Wk Range
- 1.60 - 16.40
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Scinai Immunotherapeutics Ltd.
Profil ansehen →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.